TOP-5 Price Targets of Analysts on 21.08.25
Reading Time: 4 minutes
Axsome Therapeutics [US05464T1043] RBC Capital confirms Buy rating with a price target of 189 USD (62% upside potential) The assessment is based on the strong financial performance of the company in the second quarter as well as the promising potential of the drug AXS-05, which is being developed for the treatment of agitation in Alzheimer’s patients. RBC emphasizes that Axsome ’s revenue of 150 million USD has exceeded expectations, and the loss per share was also less than anticipated. The analyst is particularly optimistic about...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
